

LIST OF TABLES

1.1 List of Tables

Table 1:Symptoms of AD

Table 2:Guidelines for the Treatment of AD

Table 3:Most Prescribed Drugs for AD by Class in the Global Markets, 2012

Table 4:Leading Branded Treatments for AD, 2013

Table 5:Product Profile - Aricept

Table 6:Aricept SWOT Analysis, 2013

Table 7:Product Profile- Exelon

Table 8:Exelon SWOT Analysis, 2012

Table 9:Product Profile - Razadyne

Table 10:Razadyne SWOT Analysis, 2013

Table 11:Product Profile- Namenda

Table 12:Namenda SWOT Analysis, 2013

Table 13:Overall Unmet Needs - Current Level of Attainment

Table 14:Clinical Unmet Needs - Gap Analysis, 2013

Table 15:Technology Trends Analytic Framework for the AD Pipeline, 2012

Table 16:Comparison of Therapeutic Classes in Development for AD, 2013

Table 17:Comparison of Therapeutic Classes in Development for AD, 2013

Table 18:Sales Forecasts (\$m) for AD in China, 2012-2022

Table 19:Key Events Impacting Sales for AD in China, 2012-2022

Table 20:AD Market in China - Drivers and Barriers in China, 2012-2022

1.2 List of Figures

Figure 1:Atrophy of the Brain in AD

Figure 2:Key Pathological Features in AD Versus a Healthy Neuron

Figure 3:Non-Amyloidogenic Metabolism of APP

Figure 4:Amyloidogenic Metabolism of APP

Figure 5:Neurofibrillary Tangles

Figure 6:Oxidative Damage Due to Free Radicals

Figure 7:Strategic Competitor Assessment of the Marketed Products in AD, 2013

Figure 8:AD - Pipeline Drugs by Target, 2012

Figure 9:Competitive Assessment of Late-Stage Pipeline Agents in AD, 2012-2022

Figure 10:Sales for AD in China by Drug Class, 2012-2022